Sean Wirtjes Sells 7,480 Shares of Rapid Micro Biosystems (NASDAQ:RPID) Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CFO Sean Wirtjes sold 7,480 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total value of $32,313.60. Following the sale, the chief financial officer owned 556,194 shares in the company, valued at $2,402,758.08. This trade represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Rapid Micro Biosystems Price Performance

Shares of Rapid Micro Biosystems stock opened at $2.83 on Friday. The firm has a market cap of $125.43 million, a PE ratio of -2.64 and a beta of 1.38. Rapid Micro Biosystems, Inc. has a twelve month low of $1.86 and a twelve month high of $4.94. The company has a quick ratio of 2.95, a current ratio of 4.23 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $3.97 and a 200 day moving average price of $3.54.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative return on equity of 86.01% and a negative net margin of 140.30%.The business had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.93 million. Sell-side analysts predict that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current fiscal year.

Key Headlines Impacting Rapid Micro Biosystems

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Record revenue and raised 2026 outlook — RPID reported Q4 revenue of $11.3M and full‑year 2025 revenue of $33.6M (both record levels) and set 2026 revenue guidance of $37.0M–$41.0M with 30–38 expected system placements, signaling ongoing commercial traction. GlobeNewswire: Record Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Large customer follow‑on orders — The company announced multi‑system orders from Samsung Biologics and expanded deployments with Amgen, validating Growth Direct adoption among big pharma/CDMOs and supporting recurring system + consumables revenue upside. GlobeNewswire: Samsung Biologics Order
• Positive Sentiment: Analyst commentary supports secular growth thesis — Independent write‑ups highlight big‑pharma adoption as a key growth driver that could expand recurring revenue (service/consumables) over time. Seeking Alpha: Big‑Pharma Adoption Driving Growth
• Neutral Sentiment: Guidance near consensus but execution risk remains — 2026 revenue midpoint is close to street expectations (~$39M) and gross margin guidance (~20%) is modest; outcomes depend on hitting system placement targets and margin improvement. Yahoo Finance: Q4 2025 Earnings Preview
• Neutral Sentiment: Earnings‑call tone mixed — Management emphasized commercial progress but flagged margin and scaling pressures, producing a balanced (not unequivocally bullish) message. TipRanks: Earnings Call Summary
• Negative Sentiment: EPS miss and continued unprofitability — Q4 EPS of ($0.28) missed consensus ($0.23), and the company remains loss‑making with negative margins and ROE, a key near‑term concern for shareholders. MarketBeat: Q4 Earnings
• Negative Sentiment: Insider selling by multiple senior executives — Recent Form 4 filings show CEO, CFO and COO sales (CFO sold 7,480 shares at ~$4.32; CEO and COO also sold), which can amplify selling pressure or raise questions about insider conviction. InsiderTrades: Insider Selling

Institutional Investors Weigh In On Rapid Micro Biosystems

Several large investors have recently bought and sold shares of RPID. Hudson Bay Capital Management LP acquired a new position in shares of Rapid Micro Biosystems during the third quarter valued at approximately $38,000. Fifth Lane Capital LP purchased a new position in shares of Rapid Micro Biosystems in the fourth quarter valued at approximately $51,000. American Century Companies Inc. boosted its stake in shares of Rapid Micro Biosystems by 46.1% in the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after acquiring an additional 5,341 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Rapid Micro Biosystems in the fourth quarter worth approximately $71,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Rapid Micro Biosystems during the fourth quarter worth approximately $72,000. 52.60% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RPID has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Rapid Micro Biosystems has a consensus rating of “Hold” and a consensus target price of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.